New York Heart Association

Identify signs and symptoms of heart failure and classify a given patient by the New York Heart Association Functional Classification and American College of Cardiology/American Heart Association Heart Failure Staging. 

There are two common systems for categorizing patients with HF. The New York Heart Association (NYHA) Functional Classification (FC) system is based on the patient s activity level and exercise tolerance. It divides patients into one of four classes, with functional class I patients exhibiting no symptoms or limitations of daily activities, and functional class IV patients who are symptomatic at rest (Table 3-5). The NYHA FC system reflects a subjective assessment by a health care provider and can change frequently over short periods of time. Functional class correlates poorly with EF however, EF is one of the strongest predictors of prognosis. In general, anticipated survival declines in conjunction with a decline in functional ability. 

TABLE 3-5. New York Heart Association (NYHA) Functional... 

NYHA FC New York Heart Association Functional Class... 

Prior to initiating infliximab, obtain a tuberculin skin test to rule out latent tuberculosis. Assure that patients do not have a clinically significant systemic infection or New York Heart Association Class III or IV heart failure. 

Cardiac transplantation is one option for patients with severe heart failure. Candidates for cardiac transplantation generally present with New York Heart Association (NYHA) class III or IV symptoms and have an ejection fraction of less than 25%.1,3 The general indications for cardiac transplantation include rapidly declining cardiac function and a projected 1-year mortality rate of greater than 75%. Mechanical support with an implantable left ventricular assist device may be appropriate while patients await the availability of a viable organ.1,3 Some additional reasons for heart transplant include ... 

The outcome from intraabdominal infection is not determined solely by what transpires in the abdomen. Unsatisfactory outcomes in patients with intraabdominal infections may result from complications that arise in other organ systems. A complication commonly associated with mortality after intraabdominal infection is pneumonia.26 A high APACHE (Acute Physiology And Chronic Health Evaluation) II score, a low serum albumin, and a high New York Heart Association cardiac function status were significantly and independently associated with increased mortality from intraabdominal infection.27... 

The New York Heart Association Functional Classification System is intended primarily to classify symptomatic HF patients according to the physician s subjective evaluation. Functional class (FC)-I patients have no limitation of physical activity, FC-II patients have slight limitation, FC-III patients have marked limitation, and FC-IV patients are unable to carry on physical activity without discomfort. 

Orthotopic cardiac transplantation is the best therapeutic option for patients with chronic irreversible New York Heart Association Class IV HF, with a 10-year survival of approximately 50% in well-selected patients. 

Fluid retention may occur, perhaps as a result of peripheral vasodilation and/or improved insulin sensitization with a resultant increase in renal sodium and water retention. A dilutional anemia may result, which does not require treatment. Edema is reported in 4% to 5% of patients when glitazones are used alone or with other oral agents. When used in combination with insulin, the incidence of edema is about 15%. Glitazones are contraindicated in patients with New York Heart Association Class III and IV heart failure and should be used with great caution in patients with Class I or II heart failure or other underlying cardiac disease. 

Pulmonary arterial hypertension (PAH) For the treatment of PAH in patients with New York Heart Association (NYHA) Class II to IV symptoms to diminish symptoms associated with exercise. 

NS normal saline NSAID nonsteroidal antiinflammatory drug NSCLC non small cell lung cancer NSS normal saline solution NYHA New York Heart Association OAB overactive bladder OCD obsessive-compulsive disorder OCP oral contraceptive pill (birth control pills)... 

Long-term treatment of New York Heart Association Class III and IV primary pulmonary hypertension IV Infusion Procedure to determine dose range Initially, 2 ng/kg/min, increased in increments of 2 ng/kg/min q 15min until dose-limiting adverse effects occur. Chronic Infusion Start at 4 ng/kg/min less than the maximum dose rate tolerated during acute dose ranging (or one half of the maximum rate if rate was less than 5 ng/kg/min). 

Hawthorn has long been used as a medicinal substance, and an extract such as WS 1442, a formulation of hawthorn leaves with flowers, has been evaluated in different studies for treatment of heart failure (40 2). Patients with New York Heart Association class II heart failure participated in a placebo-controlled, randomized, multicenter trial. They received 30 drops of the extract three times daily for eight weeks. At the end of the study, heart failure condition was improved (41). A meta-analysis of available clinical trials suggests that the extract is useful as an adjunct treatment for patients with mild to moderate heart failure (42). Therefore, it is likely that hawthorn products would be administered together with digoxin in clinical management of patients (Fig. 4). 

Once stage C is reached, the severity of heart failure is usually described according to a scale devised by the New York Heart Association. Class I failure is associated with no limitations on ordinary activities and symptoms that occur only with greater than ordinary exercise. Class II is characterized by slight limitation of ordinary activities, which result in fatigue and palpitations with ordinary physical activity. Class III failure results in no symptoms at rest, but fatigue, shortness of breath, and tachycardia occur with less than ordinary physical activity. Class IV is associated with symptoms even when the patient is at rest. 

In 142 patients with symptomatic heart failure (New York Heart Association classes III and IV) randomized to double-blind, placebo-controlled short-term treatment with a single intravenous dose of conivaptan 10, 20, or 40 mg, conivaptan significantly reduced pulmonary capillary wedge pressure and right atrial pressure and increased urine output (1). 

Her research into heart failure has given her some information about what types of variables she should collect. Patients with heart failure show symptoms of decreased exercise tolerance, shortness of breath, increased fatigue, and fluid buildup in the lungs and tissues. Patients with heart failure are also classified clinically by their level of disability so that they may be followed longitudinally and provide a reference point when compared with other patients. This classification system is the New York Heart Association (NYHA) Functional Classification system and ranges from functional class I (no limitation of physical activity) to functional class IV (unable to carry on physical activity without discomfort) (Criteria Committee, 1973). 

Criteria Committee, New York Heart Association, Inc. 1973. Diseases of the Heart and Blood Vessels Nomenclature and Criteria for Diagnosis, 7th ed. Boston Little, Brown. 

Abbreviations BM-MNC, bone marrow mononuclear cell CABO, coronary artery bypass grafting CPC, circulating progenitor cells LV. left ventricle LVED. left ventricular end-diastolic diameter LVEDV, left ventricular end-diastolic volume LVEF, left ventricular ejection fraction NYHA, New York Heart Association SKMB, skeletal myoblast. 

Clinical effects Angiotensin-converting enzyme inhibitors improve symptoms, New York Heart Association (NYHA) functional class, and exercise capacity in patients with HF The Captopril Multicenter Research Group (6) showed that captopril treatment improved the NYHA class in 61% of patients compared with only 24% of patients taking placebo over a 12-week period, Treadmill exercise time improved throughout the 12 weeks of the study in 24% of captopril-treated patients, but in none of the placebo-treated patients. 

Abbreviations. AIRE, acute Infarction ramipril efficacy CONSENSUS, cooperative north Scandinavian enalapril sur/f/a study HF, heart failure LVEF, left ventricular ejection fraction NYHA. New York Heart Association SAVE, survival and ventricular enlargement SMILE, survival of myocardial infarction long-term evaluation SOLVD. studies of left ventricular dysfunction TRACE, trandolapril cardiac evaluation study group. 

Abbreviations-. BEST, beta-blocker evaluation survival trial CAPRICORN, caiveclilol postinfarct suivival control in left ventricular dysfunction C1B1S II, Cardiac Insufficiency Bisoprolol Study II COMET, Carvedilol or Metoprolol European Trial COPERNICUS, carvedilol prospective randomized cumulative survival HF, heart failure LVEF, left ventricular ejection fraction MDC, metoprolol in dilated cardiomyopathy MERIT-HF, metoprolol controlled-release randomized intervention trial in congestive heart failure fJYHA, New York Heart Association. 

Abbreviations ACE, angiotensin-converting enzyme CHARM, candesartan in heart failure assessment of reduction in mortality and morbidity ELITE, evaluation of losartan in the elderly HF, heart failure LVEF, left ventricular ejection fraction Ml. myocardial infarction NYHA. New York Heart Association OFTIMAAL. optimal trial in myocardial infarction with angiotensin II antagonist losartan Val-HeFT, valsartan in heart failure trial VALIANT, valsartan in acute myocardial infarction trial. 

Anemia baseline hematocrit value <39% for men and >36% for women congestive heart failure class III/1V by New York Heart Association classification and/or history of pulmonary edema Hypotension systolic blood pressure <80mmHg for at least 1 hr requiring inotropic support with medications or intra-aortic balloon pump (IABP) within ... 

Abbrevations. CAD. coronary artery disease CHF, congestive heard failure CV, cardiovascular CVA, cerebrovascular accident ED, erectile dysfunction ETT, exercise tolerance test LVD, left ventricular dysfunction MI, myocardial infarction NYHA. New York Heart Association. 

Gietzen FH, Leuner CJ, Obergassel L, et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV and outflow obstruction only under provocable conditions. Circulation 2002 106 454-459. 

---